Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingJun 7, 2023Pilocarpine Hydrochloride Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0861-2023Class IIOngoingJun 7, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0860-2023Class IIOngoingJun 7, 2023Midazolam InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0859-2023Class IIOngoingJun 7, 2023Calcitriol Injection 2 mcg/mLCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0858-2023Class IIOngoingJun 7, 2023Amantadine Hydrochloride Oral Solution USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0857-2023Class IIOngoingJun 7, 2023XOPENEXCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0856-2023Class IIOngoingJun 7, 2023Vitamin D Supplement DropsCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0855-2023Class IIOngoingJun 7, 2023Valproic Acid Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0854-2023Class IIOngoingJun 7, 2023Tropicamide Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0853-2023Class IIOngoingJun 7, 2023Trihexyphenidyl Hydrochloride Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0852-2023Class IIOngoingJun 7, 2023Tobramycin Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0851-2023Class IIOngoingJun 7, 2023Tobramycin Inhalation Solution USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0850-2023Class IIOngoingJun 7, 2023Timolol Maleate Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0849-2023Class IIOngoingJun 7, 2023Sulfamethoxazole & Trimethoprim Oral Suspension USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0848-2023Class IIOngoingJun 7, 2023SufentaCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0847-2023Class IIOngoingJun 7, 2023Sodium DIURILCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0846-2023Class IIOngoingJun 7, 2023Sodium Chloride Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0845-2023Class IIOngoingJun 7, 2023Sodium Chloride Ophthalmic OintmentCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0844-2023Class IIOngoingJun 7, 2023Fentanyl Citrate InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0843-2023Class IIOngoingJun 7, 2023Ropivacaine Hydrochloride Injection USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0842-2023Class IIOngoingJun 7, 2023Rifampin Capsules USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0841-2023Class IIOngoingJun 7, 2023Rifampin Capsules USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0840-2023Class IIOngoingJun 7, 2023Proparacaine HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0839-2023Class IIOngoingJun 7, 2023Promethazine HCl Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0838-2023Class IIOngoingJun 7, 2023Promethazine HCl & Codeine Phosphate Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0837-2023Class IIOngoingJun 7, 2023Prednisolone Oral SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0836-2023Class IIOngoingJun 7, 2023Pilocarpine Hydrochloride Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0835-2023Class IIOngoingJun 7, 2023Oxcarbazepine Oral SuspensionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0834-2023Class IIOngoingJun 7, 2023Olopatadine HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0833-2023Class IIOngoingJun 7, 2023Olopatadine HCl Nasal SprayCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0832-2023Class IIOngoingJun 7, 2023Neomycin & Polymyxin B SulfatesCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0831-2023Class IIOngoingJun 7, 2023Naloxone InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0830-2023Class IIOngoingJun 7, 2023Moxifloxacin HCl Ophthalmic SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0829-2023Class IIOngoingJun 7, 2023Midazolam InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0828-2023Class IIOngoingJun 7, 2023Megestrol Acetate Oral SuspensionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0827-2023Class IIOngoingJun 7, 2023Lorazepam Oral ConcentrateCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0826-2023Class IIOngoingJun 7, 2023Lorazepam InjectionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0825-2023Class IIOngoingJun 7, 2023Lidocaine Hydrochloride Oral Topical SolutionCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0824-2023Class IIOngoingJun 7, 2023Lidocaine HCl Jelly USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0823-2023Class IIOngoingJun 7, 2023Lidocaine Ointment USPCGMP Deviations: Firm went out of business and could no longer continue stability studies.Akorn, Inc. · D-0822-2023